2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07C.04 Adjuvant Aumolertinib in Resected Stage I EGFR-Mutated NSCLC: Prospectively Evaluating Efficacy in Residual GGN Lesions

EP.07C.04 Adjuvant Aumolertinib in Resected Stage I EGFR-Mutated NSCLC: Prospectively Evaluating Efficacy in Residual GGN Lesions

Back to course

Pdf Summary

The study led by Chongbiao Huang evaluates the efficacy of aumolertinib, a third-generation EGFR TKI, as adjuvant therapy for patients with stage I EGFR-mutated NSCLC who have residual ground glass nodules (GGNs) post-surgery. Conducted at Tianjin Medical University Cancer Institute & Hospital, it is a prospective, single-center, phase II clinical trial (ChiCTR2200066768). The primary endpoint of the study is the response rate of GGN lesions, with secondary endpoints including objective response rate, disease-free survival, safety, and tolerability.<br /><br />31 patients with EGFR positive mutations were enrolled, with 45.2% having co-mutations. The majority of the cancers were invasive adenocarcinomas (93.5%). Over the study period, the 1-year disease-free survival rate was recorded at 100%, with no recurrence observed. The response rate for the GGN lesions was 69.4%, and the overall objective response rate was 71.0%. Notably, complete disappearance of GGNs was observed in seven patients, primarily with L858R mutation.<br /><br />During treatment, common adverse events included rash (22.6%), pruritus (19.4%), diarrhea (9.7%), mouth ulcers (6.5%), and alopecia (3.2%), but no patient discontinued treatment.<br /><br />The findings suggest that aumolertinib is effective in treating remaining GGN lesions in stage I EGFR-mutated NSCLC, particularly beneficial for patients with more complicated cases or those with the L858R mutation. The study implies further exploration is needed to fully understand the drug's potential across varying conditions of residual GGNs and mixed component lesions. The work is supported by numerous patients, caregivers, and professionals participating in the study.

Asset Subtitle

Chong Biao Huang

Meta Tag

Speaker Chong Biao Huang

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

aumolertinib

EGFR TKI

NSCLC

ground glass nodules

clinical trial

L858R mutation

disease-free survival

adverse events

EGFR mutations

Tianjin Medical University